PNU-96391

TargetMol
Product Code: TAR-T28435
Supplier: TargetMol
CodeSizePrice
TAR-T28435-1mg1mg£227.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28435-1mL1 mL * 10 mM (in DMSO)£402.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28435-5mg5mg£422.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28435-10mg10mg£589.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28435-25mg25mg£863.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28435-50mg50mg£1,179.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28435-100mg100mg£1,564.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28435-500mg500mg£3,058.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
PNU-96391 is an antagonist of dopamine D2 and a partial agonist of 5-HT2A. PNU-96391 can be used in research on the treatment of chronic diseases.
CAS:
146798-66-5
Formula:
C15H23NO2S
Molecular Weight:
281.41
Pathway:
Neuroscience; GPCR/G Protein
Purity:
0.98
SMILES:
CCCN1CC(C2=CC=CC(S(=O)(C)=O)=C2)CCC1
Target:
Dopamine Receptor; 5-HT Receptor

References

1. Yamazaki S, et al. Comparison of prediction methods for in vivo clearance of (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, a dopamine D2 receptor antagonist, in humans. Drug Metab Dispos. 2004 Apr;32(4):398-404. 2. Rodr?guez CA, et al. Single oral dose safety, tolerability, and pharmacokinetics of PNU-96391 in healthy volunteers. J Clin Pharmacol. 2004 Mar;44(3):276-83. 3. Yamazaki S, et al. Application of stable isotope methodology in the evaluation of the pharmacokinetics of (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride in rats. Drug Metab Dispos. 2009 May;37(5):937-45. 4. Wienkers LC, Wynalda MA. Multiple cytochrome P450 enzymes responsible for the oxidative metabolism of the substituted (S)-3-phenylpiperidine, (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, in human liver microsomes. Drug Metab Dispos. 2002 Dec;30(12):1372-7.